Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 25 Mar 2022 New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures Read More 25 Mar 2022 WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction Read More 18 Mar 2022 Transparency notification FMR LLC Read More 18 Mar 2022 Disposal of own shares Read More 11 Mar 2022 Disposals of own shares Read More 8 Mar 2022 UCB expands innovation footprint with new state-of-the-art gene therapy facility Read More Pagination First page Previous page Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
